- IPO Open: Aug 26 – Aug 29, 2025; Anchor Investors on Aug 25.
- Fresh Issue Size: 1.33 crore equity shares.
- Listing: NSE (designated) & BSE.
- Company: Pharma API & nutraceutical manufacturer with exports to 15 countries.
- Financials: FY25 revenue ₹12,028.66 lakh; profit ₹2,051.79 lakh.
- Objects: Working capital, debt repayment, capex, corporate purposes.
Source: SEBI
Anlon Healthcare Limited, a Gujarat-based pharmaceutical company, is set to launch its maiden Initial Public Offering (IPO) with a fresh issue of 1.33 crore equity shares of face value ₹10 each. The IPO will open for subscription on August 26, 2025, and close on August 29, 2025, with an anchor investor bidding date on August 25, 2025 .
The IPO is being managed by Interactive Financial Services Limited as the Book Running Lead Manager (BRLM), with KFin Technologies Limited as the registrar. The shares are proposed to be listed on both BSE and NSE, with NSE as the designated stock exchange.
The price band and minimum bid lot will be announced at least two working days prior to the opening.
Anlon Healthcare IPO Details at a Glance
| Particulars | Details |
|---|---|
| Issue Type | 100% Book Built Issue |
| Fresh Issue Size | Up to 1,33,00,000 equity shares (aggregating up to ₹[●] crore) |
| Offer for Sale (OFS) | Nil |
| Total Issue Size | 1.33 crore shares |
| Face Value per Share | ₹10 |
| Price Band | To be announced |
| Lot Size | Minimum bid lot [●] equity shares, multiples thereafter |
| Issue Opens | August 26, 2025 |
| Issue Closes | August 29, 2025 |
| Tentative Listing Date | Early September 2025 |
| Lead Manager | Interactive Financial Services Limited |
| Registrar | KFin Technologies Limited |
| Listing | BSE & NSE (NSE designated) |
Anlon Healthcare IPO Reservation Structure
| Category | Reservation | Notes |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | Minimum 75% of net issue | May include Anchor Investors (up to 60% of QIB portion, with 1/3rd reserved for domestic mutual funds) |
| Non-Institutional Investors (NIIs) | Up to 15% | Subdivided into applications between ₹2–10 lakh and above ₹10 lakh |
| Retail Individual Investors (RIIs) | Up to 10% | Minimum bid lot, multiples thereafter |
About Anlon Healthcare Limited
Founded in 2013, Anlon Healthcare started as Anlon Ventures Pvt. Ltd. before becoming a public limited company in 2024. Headquartered in Rajkot, Gujarat, the company is engaged in manufacturing:
- Pharmaceutical Intermediates & APIs (e.g., Loxoprofen Sodium Dihydrate, Ketoprofen, Loratadine).
- Nutraceutical Ingredients (L-Arginine, L-Carnitine, L-Glutamine).
- Personal Care Ingredients (Piroctone Olamine, Sodium Sarcosine).
- Veterinary APIs (Ketoprofen, Tolfenamic Acid).
- Custom Chemical Manufacturing with high-purity compounds.
The company operates in 15 countries including Italy, Germany, Japan, China, Brazil, UK, and UAE.
Anlon Healthcare Strengths
- Diversified Portfolio – Expertise across pharma intermediates, APIs, nutraceuticals, veterinary products, and personal care ingredients.
- Custom Chemical Manufacturing – Ability to deliver high-purity, tailor-made compounds exceeding industry standards.
- Strong R&D & QA/QC Setup – Equipped with four dedicated R&D labs, in-house quality assurance and control systems.
- Global Presence – Exports to over 15 countries with established regulatory approvals.
- Promoter Expertise – Experienced leadership of Punitkumar R. Rasadia and team with decades in the chemical-pharma domain.
- Cost Efficiency & Safety – Focus on operational efficiency, safe workplace practices, and compliance.
- Customer Relationships – Trusted by a diverse client base for customized solutions.
Anlon Healthcare Financial Performance (Restated)
| Particulars (₹ in Lakh) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue from Operations | 12,028.66 | 6,658.37 | 11,287.74 |
| Other Income | 16.85 | 10.82 | 24.25 |
| Total Income | 12,045.51 | 6,669.19 | 11,312.00 |
| Net Profit | 2,051.79 | 965.71 | 582.00 |
| EPS (₹) | 6.37 | 6.68 | 4.85 |
| Equity Share Capital | 3,985.15 | 1,600.00 | 1,200.00 |
| Reserves & Surplus | 4,057.02 | 503.14 | -462.57 |
| Debt-Equity Ratio | 3.55 | 9.00 | 38.81 |
Objects of the Issue
The net proceeds will be used for :
- Funding Capital Expenditure – Expansion of manufacturing facility (₹3,071.95 lakh).
- Debt Repayment – Partial/complete repayment of secured borrowings (₹500 lakh).
- Working Capital – Meeting working capital needs (₹4,315 lakh).
- General Corporate Purposes – For expansion and contingencies (max 25% of issue size).
Additionally, the IPO aims to enhance brand visibility, improve liquidity, and create a public market for Anlon shares in India.
Author
